Head to Head Review: Flag Ship Acquisition (ETHZ) versus Its Peers

Flag Ship Acquisition (NASDAQ:ETHZ) is one of 450 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it compare to its rivals? We will compare Flag Ship Acquisition to related businesses based on the strength of its earnings, risk, analyst recommendations, valuation, institutional ownership, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and target prices for Flag Ship Acquisition and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Flag Ship Acquisition	1	0	0	0	1.00
Flag Ship Acquisition Competitors	4780	9954	15974	365	2.38

As a group, “Pharmaceutical Preparations” companies have a potential upside of 72.63%. Given Flag Ship Acquisition’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Flag Ship Acquisition has less favorable growth aspects than its rivals.

Profitability

This table compares Flag Ship Acquisition and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Flag Ship Acquisition	N/A	-141.25%	-80.77%
Flag Ship Acquisition Competitors	-2,625.49%	-359.63%	-43.39%

Institutional and Insider Ownership

4.1% of Flag Ship Acquisition shares are held by institutional investors. Comparatively, 39.5% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 5.4% of Flag Ship Acquisition shares are held by insiders. Comparatively, 13.8% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk and Volatility

Flag Ship Acquisition has a beta of 0.38, meaning that its stock price is 62% less volatile than the S&P 500. Comparatively, Flag Ship Acquisition’s rivals have a beta of 10.34, meaning that their average stock price is 934% more volatile than the S&P 500.

Valuation & Earnings

This table compares Flag Ship Acquisition and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Flag Ship Acquisition	N/A	-$6.17 million	-0.13
Flag Ship Acquisition Competitors	$440.93 million	-$69.09 million	-9.11

Flag Ship Acquisition’s rivals have higher revenue, but lower earnings than Flag Ship Acquisition. Flag Ship Acquisition is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Flag Ship Acquisition rivals beat Flag Ship Acquisition on 9 of the 13 factors compared.

About Flag Ship Acquisition

1180 Life Sciences Corp., a clinical-stage biotechnology company, develops therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. Its product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which is under Phase IIb clinical trials that focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which is under preclinical trials that are man-made derivatives of CBD; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.